Log-in
Sign-up
Webcast
Clinical Trials
Webcast
Clinical Trials
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
ACTIVE_NOT_RECRUITING
NCT06372483
Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant
40
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE1)
Coagulation Disorder
RECRUITING
NCT05965479
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
25
Enrollment(s)
14
Study location(s)
INTERVENTIONAL (PHASE2)
Gastrooesophageal Cancer
RECRUITING
NCT04986579
Scalp Cooling in MBC
120
Enrollment(s)
2
Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Breast Cancer
Chemotherapy-induced Alopecia
RECRUITING
NCT06085755
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
61
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Stomach Neoplasm
ACTIVE_NOT_RECRUITING
NCT03523585
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
608
Enrollment(s)
227
Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
NOT_YET_RECRUITING
NCT06665178
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
20
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer
ACTIVE_NOT_RECRUITING
NCT04704934
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
490
Enrollment(s)
156
Study location(s)
INTERVENTIONAL (PHASE3)
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
COMPLETED
NCT04644237
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
152
Enrollment(s)
50
Study location(s)
INTERVENTIONAL (PHASE2)
Non-Small Cell Lung Cancer
16
17
18
19
20